March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Clinical Features And Management Of Vogt Koyanagi Harada Syndrome In Argentina
Author Affiliations & Notes
  • Veronica E. Giordano
    Uveitis, Hospital de Cli­nicas Jose de San Marti­n, Buenos Aires, Argentina
  • Ariel Schlaen
    Uveitis, Hospital de Cli­nicas Jose de San Marti­n, Buenos Aires, Argentina
  • Pablo Koll
    Uveitis, Hospital de Cli­nicas Jose de San Marti­n, Buenos Aires, Argentina
  • Noelia Paira
    Uveitis, Hospital de Cli­nicas Jose de San Marti­n, Buenos Aires, Argentina
  • Pablo Chiaradia
    Uveitis, Hospital de Cli­nicas Jose de San Marti­n, Buenos Aires, Argentina
  • Cristobal Couto
    Uveitis, Hospital de Cli­nicas Jose de San Marti­n, Buenos Aires, Argentina
  • Footnotes
    Commercial Relationships  Veronica E. Giordano, None; Ariel Schlaen, None; Pablo Koll, None; Noelia Paira, None; Pablo Chiaradia, None; Cristobal Couto, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 1204. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Veronica E. Giordano, Ariel Schlaen, Pablo Koll, Noelia Paira, Pablo Chiaradia, Cristobal Couto; Clinical Features And Management Of Vogt Koyanagi Harada Syndrome In Argentina. Invest. Ophthalmol. Vis. Sci. 2012;53(14):1204.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To describe the clinical features and management of Vogt Koyanagi Harada (VKH) patients (p) in an argentine population.

Methods: : A retrospective chart review of 105 VKH p who attended at the Uveitis clinic from january 1980 to december 2008, were analyzed. Patients were classified according to the initiation of treatment. Group 1: High dose of corticosteroids within 2 weeks of illness onset. Group 2: High dose of corticosteroids after 2 weeks of illness onset but before a month. Group 3: Low doses of corticosteroids, or high dose but > 1 month of illness onset.

Results: : There were 210 eyes. Mean age of patients was 43,76 ±14 years, mean age of illness onset was 32,64 ±13 years, mean disease duration 144 ±96,62 months. Exudative retinal detachment was the most frequent symptom at onset (45,69%). Patients on high dose steroids (n=56) had significantly higher visual acuity compared to those who did not (n=136), (p<0,0001), and none of them had light perception at the end of follow up, while 13,14% of patients in Group 3 had light perception (p<0,004). Complications occurred more frequently in Group 3 compared to Group 1, 78,79% vs 56,14% (p=0,001), and in Group 2 (58,62%) vs Group 3 (77,86%) (p=0,001).

Conclusions: : Patients with early high dose of corticosteroids and adequate time of exposure presented better visual acuity and less complications.

Keywords: uvea • clinical (human) or epidemiologic studies: outcomes/complications • choroid 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×